Peritoneal Recurrence of Cecal Cancer with Specific Imaging Findings and Shrinkage after Treatment with Pembrolizumab.
MSI-H
colorectal cancer
dMMR
pembrolizumab
peritoneal recurrence
Journal
Journal of the anus, rectum and colon
ISSN: 2432-3853
Titre abrégé: J Anus Rectum Colon
Pays: Japan
ID NLM: 101718055
Informations de publication
Date de publication:
2022
2022
Historique:
received:
20
08
2021
accepted:
11
10
2021
entrez:
7
2
2022
pubmed:
8
2
2022
medline:
8
2
2022
Statut:
epublish
Résumé
Pembrolizumab is one of the treatment options for treatment-refractory unresectable advanced or metastatic colorectal cancer with microsatellite instability-high (MSI-H) or deficiencies in DNA mismatch repair (dMMR). Herein, we report a case in which a recurrent cecal cancer lesion showed specific imaging findings and local inflammatory findings during treatment with pembrolizumab, followed by marked shrinkage. The patient was an 80-year-old woman. Postoperative peritoneal recurrence of cecal cancer of approximately 7 cm in size was observed. The patient had MSI-H and was treated with pembrolizumab. After five courses of treatment, the patient presented to our hospital with a chief complaint of abdominal pain. A blood test showed a strong inflammatory reaction, and computed tomography (CT) showed diffuse low-density area in the tumor. Under the suspicion of an abscess, conservative treatment was initiated and the patient quickly recovered. A CT at 1 month showed a marked reduction in size at the same site, and a CT at 3 months showed that the recurrent foci had almost disappeared. The inflammatory reaction before shrinkage in this case may have been caused by tumor immune response to pembrolizumab.
Identifiants
pubmed: 35128139
doi: 10.23922/jarc.2021-053
pmc: PMC8801249
doi:
Types de publication
Case Reports
Langues
eng
Pagination
67-71Informations de copyright
Copyright © 2022 by The Japan Society of Coloproctology.
Déclaration de conflit d'intérêts
Conflicts of Interest There are no conflicts of interest.
Références
Clin Cancer Res. 2014 Oct 15;20(20):5322-30
pubmed: 25139339
Br J Cancer. 2009 Jan 27;100(2):266-73
pubmed: 19165197
Oncologist. 2008;13 Suppl 4:2-9
pubmed: 19001145
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Int Immunopharmacol. 2018 May;58:125-135
pubmed: 29579717
J Clin Oncol. 2020 Jan 1;38(1):11-19
pubmed: 31725351
Respir Med Case Rep. 2017 Aug 29;22:197-202
pubmed: 28879076
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
J Clin Oncol. 2015 Nov 1;33(31):3541-3
pubmed: 26261262
Lung Cancer. 2017 Nov;113:4-6
pubmed: 29110847
Ann Oncol. 2014 May;25(5):1032-8
pubmed: 24585723
J Thorac Oncol. 2019 May;14(5):e108-e109
pubmed: 31027746